Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience by Hwang, Eugene et al.
Korean Journal of Urology




Efficacy and Safety of Sunitinib on Metastatic Renal Cell 
Carcinoma: A Single-Institution Experience
Eugene Hwang, Hyo Jin Lee
1, Chong Koo Sul, Jae Sung Lim
Departments of Urology, 
1Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea
Purpose: We assessed the efficacy and safety of the tyrosine kinase inhibitor sunitinib 
in Korean patients with metastatic renal cell carcinoma (mRCC). 
Materials and Methods: Between September 2007 and December 2009, all twenty-one 
patients who had mRCC with a clear-cell component were retrospectively reviewed. 
Sunitinib was administered orally at a dose of 50 mg daily until disease progression 
or intolerance to treatment occurred. The primary end point of this study was the ob-
jective tumor response assessed by Response Evaluation Criteria in Solid Tumors 
(RECIST), and the secondary end points were progression-free survival (PFS) and over-
all survival (OS) rates as well as assessment of adverse effects. 
Results: After a median of 17.4 months (range, 5.7-33.1 months) of treatment, 11 pa-
tients (52.4%) had an objective response with a complete response in 1 patient (4.8%), 
and a partial response in 10 patients (47.6%) as the best tumor response. The median 
PFS was 13.4 months (95% confidence interval [CI], range, 12.3-14.5 months), and the 
median OS was 28.1 months (95% CI, 21.8-34.4 months). All patients experienced ad-
verse events of some sort, but the studied treatment protocol was well tolerated and 
most patients experienced reversible grade 1 or 2 toxicities. 
Conclusions: Sunitinib was efficacious in the treatment of metastatic clear-cell RCC, 
and was well tolerated in Korean patients. Although sunitinib treatment-related ad-
verse events such as hand-foot syndrome and facial/generalized edema were observed 
with a higher incidence than in Western trials, they were mainly mild to moderate, and 
readily managed. 
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Renal cell carcinoma (RCC) is the most common malig-
nancy of the kidney [1]. Although surgery is curative for lo-
calized disease, up to 30% of patients with RCC present 
with metastatic disease at the time of diagnosis [2,3], and 
more than 25% of patients with locally advanced RCC de-
velop distant metastasis despite curative resection [4]. 
Since RCC is highly resistant to chemotherapy, high dose 
interleukin-2 or interferon-alfa therapy is widely used as 
a first-line treatment of metastatic disease, but they pro-
vide only a modest response rate of less than 20% [5]. Thus, 
the outcome of metastatic RCC is quietly depressing: The 
5-year overall survival rate is less than 10% [3]. Effective 
systemic therapy for RCC is mandatory.
　In conventional RCC, the loss of von Hippel-Lindau pro-
tein function leads to overexpression of vascular endothe-
lial growth factor (VEGF) and platelet-derived growth fac-
tor that promote tumor angiogenesis [6,7]. Sunitinib is an 
orally active multi-targeted tyrosine kinase inhibitor that 
specifically inhibits VEGF receptor (VEGFR), platelet- de-
rived growth factor receptor (PDGFR), FMS-like tyrosine 
kinase-3 (flt-3), and stem c-Kit protein (c-Kit) [8]. The effi-
cacy on metastatic RCC has been confirmed in both phase 
II and III trials, where it was shown to improve the median 
progression-free survival (PFS), yield a higher response Korean J Urol 2010;51:450-455
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  1 68 Favorable Lung, liver Nephrectomy 29.5 17 PR
  2 60 Favorable Lung Radiotherapy 20 12 PR
  3 63 Favorable L/N Cytokine, nephrectomy,
  radiotherapy
33.1 19 PR
  4 61 Favorable Liver Nephrectomy 18 10 SD
  5 75 Intermediate L/N Cytokine, nephrectomy 26.7 13 CR
  6 67 Intermediate Lung Cytokine, nephrectomy 13   7 PR
  7 57 Intermediate Lung, L/N Cytokine, nephrectomy 28.1 17 PR
  8 67 Intermediate Bone, liver Nephrectomy   8.3   5 PR
  9 64 Intermediate Lung Radiotherapy 24.1 15 PR
10 55 Intermediate Lung 15.6   9 PR
11 62 Intermediate Lung, L/N   9.9   5 SD
12 69 Intermediate  Bone, adrenal gland 23.2 11 SD
13 75 Intermediate Lung, pancreas Nephrectomy 17 11 SD
14 70 Intermediate Lung, L/N Cytokine, nephrectomy 14.3   8 PD
15 67 Poor Lung Cytokine, nephrectomy 19.3 12 PR
16 54 Poor Lung, L/N Cytokine, nephrectomy 25.6 15 PR
17 68 Poor Bone, lung, L/N Nephrectomy   9.7  6 SD
18 46 Poor Bone, L/N 10.5  6 SD
19 53 Poor Adrenal gland, bone, lung, L/N   6.2  3 SD
20 69 Poor Bone, lung Nephrectomy   9.3  4 PD
21 73 Poor Bone, lung 　   5.7  3 PD
MSKCC: Memorial Sloan-Kettering Cancer Center, PR: partial response, L/N: lymph nodes, SD: stable disease, CR: complete response, 
PD: progressive disease
rate (RR), and afford a better quality of life over interfer-
on-alfa [9-11]. Based on current data, sunitinib is now the 
preferred drug for first-line treatment of metastatic RCC 
[10,11].
　However, these studies were performed mainly in 
Western populations. The difference in behaviors of RCC 
in different ethnic groups has been demonstrated [12]. 
Although the nature of these variations and associated mo-
lecular basis is not demonstrated, it is reasonable to eval-
uate the efficacy of sunitinib on metastatic RCC in those 
of different ethnic backgrounds. Therefore, we perfomed 
this retrospective study to assess the efficacy and safety of 
sunitinib in Korean patients with metastatic RCC using an 
institutional treatment protocol. 
MATERIALS AND METHODS
1. Patients
The medical records of patients treated with sunitinib for 
metastatic RCC were retrospectively reviewed between 
September 2007 and December 2009. The inclusion cri-
teria were as follows: histologically confirmed clear-cell 
RCC; metastases measurable on computed tomography 
(CT) or magnetic resonance imaging (MRI); a performance 
status of 0-2 based on Eastern Cooperative Oncology Group 
(ECOG) criteria. Patients were excluded if they had brain 
metastases. A total of 21 patients were found to fit the study 
criteria. Patient demographics, prior therapy, best re-
sponses, and relevant toxicities were obtained from medi-
cal records, and survival data were collected by telephone 
interviews. Risk factors associated with shorter survival 
were assessed according to the Memorial Sloan-Kettering 
Cancer Center (MSKCC) risk classification: a low serum 
hemoglobin level, an elevated corrected serum calcium lev-
el, an elevated serum lactate dehydrogenase level, a poor 
performance status, and an interval of less than 1 year be-
tween diagnosis and treatment [12].
2. Treatment schedule
Sunitinib was administered orally at a dose of 50 mg daily, 
consisting of 4 weeks of treatment followed by a 2-week rest 
period in cycles of 6 weeks (schedule 4-2). Dose reduction 
of sunitinib was allowed to 37.5 mg and then 25 mg daily 
depending on the type and severity of adverse events. 
Treatment with sunitinib was continued until the occur-
rence of disease progression, unacceptable adverse events, 
or patient withdrawal.
3. Study end points
The primary end point of this study was the objective clin-
ical response (complete response, partial response, stable 
disease, or progressive disease), assessed by Response 
Evaluation Criteria in Solid Tumors (RECIST) using regu-
lar physical examinations, CT/MRI, and bone scans (if bone 
metastases were present at baseline) after each cycle for 
the first 4 cycles thereafter until the end of treatment [13]. Korean J Urol 2010;51:450-455
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TABLE 2. Patient characteristics
Characteristics No. of patients (%)
Total patients 21 (100)
Sex
  Male 17 (81)
  Female 4 (19)
Median age-year (range) 63.9 (46-75)
ECOG performance status
  0 12 (57.1)
  1   6 (28.6)
  2   3 (14.3)
Previous treatment
  Cytokine   7 (33.3)
  Radiation therapy   3 (14.3)
  Nephrectomy 13 (61.9)
Sites of metastasis
  Lung 15 (71.4)
  Liver   3 (14.3)
  Bone   7 (33.3)
  Lymph nodes   9 (42.9)
No. of disease sites
  1   8 (38.1)
  2 10 (47.6)
  ≥3   3 (14.3)
MSKCC risk factors
  Favorable (0)   4 (19.0)
  Intermediate (1,2) 10 (47.6)
  Poor (≥3)   7 (33.3)
ECOG: Eastern Cooperative Oncology Group. MSKCC: Memo-
rial Sloan-Kettering Cancer Center
FIG. 1. Progression-free survival in Korean patients with 
metastatic clear-cell renal-cell carcinoma.
TABLE 3. Best response




Objective response 11 (52.4)
    Complete response 1 (4.8)
    Partial response 10 (47.6)
Stable disease for ≥3 months   7 (33.3)
Progressive disease or stable disease ＜3 months   3 (14.3)
a: tumor response was assessed by Response Evaluation Criteria
In Solid Tumor
The secondary end points were progression free survival 
(PFS) and overall survival (OS) rates. PFS was defined as 
the time from the start of treatment to the date of pro-
gressive disease or death. OS was defined as the time from 
start of treatment to death or the date at which patients 
were last known to be alive.
　The adverse events secondary to treatment were eval-
uated at each visit according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTCAE, version 3.0).
4. Statistical analysis
Estimates of median PFS and OS were calculated using the 
Kaplan-Meier method, and 95% CIs were considered stat-




Between July 2007 and March 2010, all twenty-one pa-
tients who had metastatic RCC with a clear-cell component 
were included in the analysis (Table 1, 2). There were 17 
males (81%) and 4 females (19%), and the median age was 
63.9 (range, 46-75 years). Of those patients, 4 patients 
(19.0%) had low-risk disease, 10 patients (47.6%) had inter-
mediate-risk disease, and 7 patients (33.3%) had high-risk 
disease according to the MSKCC criteria. The previous 
treatments were as follows: previous nephrectomy in 13 pa-
tients (61.9%), cytokine therapy in 7 patients (33.3%), and 
radiation therapy in 3 patients (14.3%). The most preva-
lent sites of metastases were as follows: the lung in 15 pa-
tients (71.4%), lymph nodes in 9 patients (42.9%), bone in 
7 patients (33.3%), and liver in 3 patients (14.3%). 
2. Treatment outcomes
After a median of 17.4 months (range, 5.7-33.1 months) of 
treatment, 14 patients (66.7%) remained alive with the dis-
ease, and treatment was ongoing in 11 patients (52.4%). 
Reasons for discontinuing treatment were progressive dis-
ease in 2 patients and adverse events in 1 patient. Accor-
ding to assessment with the RECIST criteria, 11 patients 
(52.4%) had an objective response rate, with a complete re-
sponse in 1 patient (4.8%), and a partial response in 10 pa-
tients (47.6%) as the best tumor response rate (Table 3). The 
median PFS was 13.4 months (95% confidence interval 
[CI], range, 12.3-14.5 months) (Fig. 1), and the median OS 
was 28.1 months (95% CI, 21.8-34.4 months) (Fig. 2). 
3. Adverse events
All patients experienced adverse events of some sort: fa-Korean J Urol 2010;51:450-455
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FIG. 2. Overall survival in Korean patients with metastatic 
clear-cell renal-cell carcinoma.
TABLE 4. Treatment-related adverse events and laboratory 
abnormalities
Adverse events
No. of all 
grades
a (%)
No. of grade 
3 or 4 (%)
Treatment-related adverse events 
Fatigue 13 (61.9)  3 (14.3)
Diarrhea 12 (57.1)  0 (0)
Hand-foot syndrome 12 (57.1)  4 (19.0)
Nausea/vomitting 10 (47.6)  0 (0)
Facial edema   9 (42.9)  0 (0)
Generalized edema   7 (33.3)  1 (4.8)
Dyspepsia   7 (33.3)  0 (0)
Stomatitis/mucositis   6 (28.6)  0 (0)
Rash   6 (28.6)  2 (9.5)
Skin discoloration   4 (19.0)  3 (14.3)
Constipation   4 (19.0)  0 (0)
Hypertension   2 (9.5)  0 (0)
Alopecia   1 (4.8)  0 (0)
Laborayory abnormalities
Neutropenia   9 (42.9)  6 (28.6)
Hepatic dysfunction   8 (38.1)  1 (4.8)
Anemia   7 (33.3)  4 (19.0)
Increased amylase/lipase   7 (33.3)  0 (0)
Thrombocytopenia   5 (23.8)  6 (28.6)
Renal insufficiency   4 (19.0)  3 (14.3)
Hyponatremia   3 (14.3)  2 (9.5)
Hypernatremia   2 (9.5)  0 (0)
Hyperkalemia   2 (9.5)  0 (0)
Hypokalemia   1 (4.8)  1 (4.8)
Hypothyroidism   1 (4.6)  0 (0)
a: adverse effects were graded according to the National Cancer
Institute Common Terminology Criteria for Adverse Events 
ver. 3.0
tigue, diarrhea, and hand-foot syndrome were the most 
common adverse effects. However, the treatment protocol 
under study was well tolerated and most patients experi-
enced reversible grade 1 or 2 toxicities (Table 4). The most 
commonly observed severe adverse events were hand-foot 
syndrome, fatigue, and generalized edema; hand-foot syn-
drome was observed in 4 patients (19.0%), fatigue was ob-
served in 3 patients (14.3%), and generalized edema was 
observed in 3 patients (14.3%) as grade 3 or 4. 
　The most common laboratory abnormalities of grade 3 
or 4 were neutropenia, thrombocytopenia, and anemia, 
with neutropenia in 6 patients (28.6%), thrombocytopenia 
in 6 patients (28.6%), and anemia in 4 patients (19.0%). 
Neutropenia was observed in 6 patients (28.6%), but there 
was no occurrence of associated fever or sepsis. Thrombocy-
topenia was observed in 6 patients (28.6%), but there was 
no clinical significance such as bleeding tendencies. 1 pa-
tient (4.8%) experienced hypothyroidism and needed thy-
roid hormone replacement. A total of 6 patients (29%) re-
quired dose reduction from 50 mg/day to 37.5 mg/day with 
further reductions to 25 mg/day due to grade 3 or 4 adverse 
events, and 1 patient (4.8%) discontinued treatment due 
to severe adverse events. The remaining 14 patients 
(66.7%) tolerated and continued treatment with a standard 
dose of sunitinib.
DISCUSSION
RCC is one of the most challenging malignancies with a dis-
mal prognosis because of the modest response to conven-
tional cytotoxic chemotherapeutic agents and limited sen-
sitivity to radiation therapy [14]. Cytokine therapy with in-
terferon-alfa or IL-2 have been the main treatment options 
for metastatic disease, but these agents have limited effi-
cacy and are associated with considerable toxic effects. 
Recent advances in understanding the molecular biology 
of RCC have led to the development of several systemic 
therapeutic agents targeting the VEGF and mammalian 
target of rapamycin (mTOR) pathways as first and second 
line treatments for metastatic disease, with impressive im-
provements in oncologic outcome [11,15]. 
　Sunitinib is one of several agents, including sorafenib, 
bevacizumab, and temsirolimus, which target the in-
hibition of pro-angiogenic growth factor activity and have 
shown favorable results in clinical trials against meta-
static clear-cell RCC [15-17]. Recent studies have con-
firmed the efficacy of sunitinib as a first line treatment for 
metastatic clear-cell RCC [10,11], but these series were 
mainly performed in different ethnicities in Western 
countries. Thus, the potential ethnic differences in the effi-
cacy and safety of sunitinib have not been established. This 
study evaluated whether Korean patients with metastatic 
RCC had comparable oncologic outcomes and safety as pa-
tients in previous randomized studies. 
　In patients with a poor prognosis according to the 
MSKCC criteria, temsirolimus is recommended as a 
first-line treatment, with sunitinib as a viable alternative 
[18], but temsirolimus is not available for Korean patients 
because of problems related to the insurance system; more 
patients with poor prognostic factors were included in this 
study. In terms of he MSKCC criteria, 33.3% of patients 
were in the poor prognosis group. Considering the selection Korean J Urol 2010;51:450-455
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bias of randomized controlled trials which include rela-
tively more favorable or intermediate risk group, the re-
sults of this study seem to reflect more reliable results in 
Korean clinical practice.
　For the treatment outcome, sunitinib treatment showed 
an objective response rate of 39% (range, 34-44%) and a 
PFS of 11.0 months (range, 10.7-13.4 months) as well as an 
OS of 26.4 months (range, 23.0-32.9 months) in previous 
phase III randomized trials [10,11]. In the current study, 
the objective response rate was 52.4%, which included a 
complete response of 4.8%, and a partial response of 47.6% 
as the best response rates. The median PFS and OS were 
13.4 months and 28.1 months, respectively. Even though 
it is difficult to directly compare this retrospective study 
with previous randomized trials, it is obvious that meta-
static RCC patients benefitted from sunitinib treatment. 
　All patients experienced treatment-related adverse 
events, the majority of which were grade 1 or 2 in severity. 
Fatigue, diarrhea, and hand-foot syndrome were the most 
frequent adverse events, but grade 3 or 4 adverse events 
were not frequent and were manageable. Most of patients 
were able to resume sunitinib treatment following dose re-
duction, and only 1 patient among all cases discontinued 
because of serious adverse events. Previous trials have re-
ported that side effects of sunitinib treatment were rever-
sible and tolerable; patients with grade 3 or 4 side effects 
did not exceed 10% [10,11]. 
　Nevertheless, routine monitoring such as evaluation of 
blood pressure/ejection fraction and a thyroid function test 
is recommended because there is possibility of serious ad-
verse events. Emerging safety data indicate that cardiotox-
icity may be associated with sunitinib; left ventricular dys-
function is the main cardiac side effect of sunitinib and 
might be partly a result of cardiomyocyte toxicity ex-
acerbated by hypertension [19]. Therefore, blood pressure 
and left ventricular ejection fraction should be monitored, 
especially in patients with cardiac risk factors. It is re-
ported that in patients treated with sunitinib, 85% of pa-
tients had abnormal results on thyroid function tests, in-
cluding elevation of thyroid stimulating hormone levels, 
decreased T3 levels, and less commonly, decreased T4 or 
free-thyroxine index levels [20]. Because an abnormal thy-
roid function test may rapidly progress from mild to pro-
found, regular surveillance is warranted at baseline and 
every 2-3 months [21].
　In terms of adverse events, neutropenia, thrombocytope-
nia, and anemia were the most frequent grade 3 or 4 labo-
ratory abnormalities reported previously [10,11], and most 
of them were improved by dose reduction. Neutropenia was 
observed in 6 patients (28.6%), but there was no event of 
associated fever or sepsis; thrombocytopenia was observed 
in 6 patients (28.6%), but there was no clinical significance 
such as bleeding tendencies; anemia increased amylase/li-
pase was observed in 7 patients (33.3%), but there were no 
associated clinical manifestations of pancreatitis.
　Compared to Western trials, sunitinib treatment in 
Korean patients achieved favorable oncological outcomes 
in terms of objective response rate, PFS, and OS. It is inter-
esting to note that the favorable outcomes of the current 
study are consistent with previous Korean studies [22,23]. 
Although the underlying reason for such a discrepancy re-
mains unclear at this time, one possible explanation is the 
inherent differences caused by ethnic backgrounds. Fur-
ther large prospective studies are required to clarify 
whether the ethnic background and its associated molec-
ular mechanisms contribute to the difference in the efficacy 
of sunitinib across ethnic groups. In terms of adverse ef-
fects, a higher incidence of hand-foot syndrome and fa-
cial/generalized edema were observed relative to Western 
trials, but they were mainly mild to moderate, and man-
aged readily.
　There are some limitations to this analysis. This was a 
retrospective analysis of a small number of patients treat-
ed at a single institution, which allows for potential se-
lection bias. Furthermore, survival benefit may not be 
weighted properly because this was not a randomized con-
trolled trial. However, this study provides evidence of the 
clinical benefits of sunitinib treatment. Sunitinib was effi-
cacious and was well tolerated in Korean patients; the ob-
jective response rate, PFS, and OS in Korean patients were 
compatible with the oncologic outcomes in previous 
randomized trials. Further large prospective inves-
tigations are required to clarify such favorable efficacy pro-
files in Korean patients.
CONCLUSIONS
Sunitinib was efficacious in the treatment of metastatic 
clear-cell RCC, and was well tolerated in Korean patients. 
The objective response rate, PFS, and OS in Korean pa-
tients were compatible with the benefits shown in previous 
randomized trials. Although sunitinib treatment-related 
adverse events such as hand-foot syndrome and facial/gen-
eralized edema were observed in higher incidence than in 
Western trials, they were mainly mild to moderate, and 
readily managed. This study encourages the target ther-
apy of sunitinib in Koreans for metastatic RCC.
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